Difference between revisions of "CT Angiography Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
m
 
(One intermediate revision by the same user not shown)
Line 23: Line 23:
  
 
==Profile Development==
 
==Profile Development==
−
 
+
*[[Media:Atherosclerosis_Biomarkers_Profile_Jun2024.pdf|''CT Atherosclerosis Biomarkers, Clinically Feasible Profile: Maintenance draft (June, 2024)''&nbsp;&nbsp;<b>DOI:10.1148/QIBA/202406</b>]]</td nowrap>
 +
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|'''CT Atherosclerosis Biomarkers, Clinically Feasible Profile. (March 28, 2023)''' &nbsp;&nbsp;<b>DOI:10.1148/QIBA/20230328</b>]]
 
*[[Media:QIBA CTA Profile as of 2023-Feb-16.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]]
 
*[[Media:QIBA CTA Profile as of 2023-Feb-16.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]]
 
*[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]]
 
*[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]]

Latest revision as of 15:22, 11 July 2024

Co-chairs: Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT


Meetings

Recent Call Summaries:

CT Angiography Call Summaries Archive

Project Snapshot - CT Angiography

The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).

Excerpt from the biomarker committee submission form:

The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.

Profile Development

Atherosclerosis Biomarkers Profile Draft Archive

Groundwork Projects

Reference Materials

Conformance Materials

Retrieved from "https://qibawiki.rsna.org/index.php?title=CT_Angiography_Biomarker_Ctte&oldid=19745"